November 29, 2016 - By Clifton Ray
The insider, and Repligen Corp’s Chief Executive Officer, Anthony Hunt, made a sale of 5,000 company shares on November 29, 2016, worth roughly $165,613 (at $33.1 a share). The deal was revealed in a 4F filing which was filed with the (SEC) on November 29, 2016, which is available for access here. This trade decreased his ownership of the Company to 0.20% market capitalization or 68,342 shares.
Out of 2 analysts covering Repligen (NASDAQ:RGEN), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Repligen has been the topic of 2 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, February 22 by Craig Hallum. The company was downgraded on Friday, November 6 by Jefferies.
Insitutional Activity: The institutional sentiment decreased to 0.93 in 2016 Q2. Its down 0.44, from 1.37 in 2016Q1. The ratio turned negative, as 18 funds sold all Repligen Corporation shares owned while 49 reduced positions. 20 funds bought stakes while 72 increased positions. They now own 29.03 million shares or 0.27% more from 28.95 million shares in 2016Q1.
Parametric Portfolio Assoc Limited Liability reported 44,050 shares or 0% of all its holdings. The North Carolina-based Franklin Street Advisors Nc has invested 0.1% in Repligen Corporation (NASDAQ:RGEN). Moreover, Millennium Mgmt Ltd Llc has 0.01% invested in Repligen Corporation (NASDAQ:RGEN) for 138,902 shares. Blackrock Ltd Liability Co accumulated 0% or 88,528 shares. Nicholas Investment Prtnrs Lp accumulated 132,008 shares or 0.25% of the stock. Blackrock reported 54,090 shares or 0% of all its holdings. Principal Fin Group has 236,825 shares for 0.01% of their US portfolio. Eventide Asset Mngmt Ltd Limited Liability Company last reported 0.18% of its portfolio in the stock. Globeflex Capital L P last reported 0.27% of its portfolio in the stock. Palisade Management Limited Nj holds 0.72% of its portfolio in Repligen Corporation (NASDAQ:RGEN) for 720,318 shares. Moreover, Rice Hall James Assocs Limited has 0.12% invested in Repligen Corporation (NASDAQ:RGEN) for 73,636 shares. The Virginia-based Virginia Retirement System Et Al has invested 0% in Repligen Corporation (NASDAQ:RGEN). Dimensional Fund L P has 0.02% invested in the company for 1.05 million shares. Qs Invsts Lc reported 159,214 shares or 0.04% of all its holdings. Solaris Asset Management Ltd Llc has 0.01% invested in the company for 600 shares.
Insider Transactions: Since June 30, 2016, the stock had 0 insider buys, and 2 selling transactions for $220,989 net activity. Another trade for 2,700 shares valued at $87,979 was sold by RYAN THOMAS F JR.
The stock increased 1.27% or $0.42 during the last trading session, hitting $33.42. About 311,965 shares traded hands or 11.87% up from the average. Repligen Corporation (NASDAQ:RGEN) has risen 22.22% since April 26, 2016 and is uptrending. It has outperformed by 16.96% the S&P500.
Repligen Corporation is a bioprocessing company. The company has a market cap of $1.10 billion. The Firm is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs . It has a 164.31 P/E ratio. The Firm is a maker of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
According to Zacks Investment Research, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUSÂ® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.”
Analysts await Repligen Corporation (NASDAQ:RGEN) to report earnings on February, 23. They expect $0.07 EPS, 0.00% or $0.00 from last year’s $0.07 per share. RGEN’s profit will be $2.30M for 119.36 P/E if the $0.07 EPS becomes a reality. After $0.08 actual EPS reported by Repligen Corporation for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.
More important recent Repligen Corporation (NASDAQ:RGEN) news were published by: Fool.com which released: “3 Important Things You Need to Know About Repligen Corporation’s Q3 Results” on November 03, 2016, also Marketwatch.com published article titled: “Virtual Stock Exchange”, Fool.com published: “Read This Before You Sell Repligen Corporation Stock” on April 04, 2016. More interesting news about Repligen Corporation (NASDAQ:RGEN) was released by: Fool.com and their article: “Why Repligen Corporation Shares Are Falling” with publication date: November 06, 2015.
Repligen Corporation, incorporated on May 29, 1981, is a bioprocessing company. The Firm is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Firm is a maker of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. It also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Firm has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Firm makes and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, and ATF products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors. The Firm makes its products in production facilities in the United States and Sweden. The Firm markets its products globally through a direct commercial organization in the United States, Europe and Asia, as well as through strategic partners in select markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray